Yayınlar

ULUSLARARASI HAKEMLİ DERGİLERDE YAYIMLANAN MAKALELER

111 results
 

Determinants of therapeutic lag in multiple sclerosis.

Roos I, Leray E, Frascoli F, Casey R, Brown JWL, Horakova D, Havrdova EK, Debouverie M, Trojano M, Patti F, Izquierdo G, Eichau S, Edan G, Prat A, Girard M, Duquette P, Onofrj M, Lugaresi A, Grammond P, Ciron J, Ruet A, Ozakbas S, De Seze J, Louapre C, Zephir H, Sá MJ, Sola P, Ferraro D, Labauge P, Defer G, Bergamaschi R, Lebrun-Frenay C, Boz C, Cartechini E, Moreau T, Laplaud D, Lechner-Scott J, Grand’Maison F, Gerlach O, Terzi M, Granella F, Alroughani R, Iuliano G, Van Pesch V, Van Wijmeersch B, Spitaleri D, Soysal A, Berger E, Prevost J, Aguera-Morales E, McCombe P, Castillo Triviño T, Clavelou P, Pelletier J, Turkoglu R, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Sidhom Y, Gouider R, Csepany T, Bourre B, Al Khedr A, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanche JP, Maurousset A, Patry I, Hankiewicz K, Pottier C, Maubeuge N, Labeyrie C, Nifle C, Coles A, Malpas CB, Vukusic S, Butzkueven H, Kalincik T.Mult Scler. 2021 Jan 11:1352458520981300. doi: 10.1177/1352458520981300. Online ahead of print.PMID: 33423618
 
 

Effect of Disease Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.

Kalincik T, Diouf I, Sharmin S, Malpas C, Spelman T, Horakova D, Havrdova EK, Trojano M, Izquierdo G, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Jokubaitis V, van der Walt A, Grand’Maison F, Sola P, Ferraro D, Shaygannejad V, Alroughani R, Hupperts R, Terzi M, Boz C, Lechner-Scott J, Pucci E, Van Pesch V, Granella F, Bergamaschi R, Spitaleri D, Slee M, Vucic S, Ampapa R, McCombe P, Ramo-Tello C, Prevost J, Olascoaga J, Cristiano E, Barnett M, Saladino ML, Sanchez-Menoyo JL, Hodgkinson S, Rozsa C, Hughes S, Moore F, Shaw C, Butler E, Skibina O, Gray O, Kermode A, Csepany T, Singhal B, Shuey N, Piroska I, Taylor B, Simo M, Sirbu CA, Sas A, Butzkueven H; MSBase Study group.Neurology. 2020 Dec 28:10.1212/WNL.0000000000011242. doi: 10.1212/WNL.0000000000011242. Online ahead of print.PMID: 33372028
 
 

Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a.

Bovis F, Kalincik T, Lublin F, Cutter G, Malpas C, Horakova D, Havrdova EK, Trojano M, Prat A, Girard M, Duquette P, Onofrj M, Lugaresi A, Izquierdo G, Eichau S, Patti F, Terzi M, Grammond P, Bergamaschi R, Sola P, Ferraro D, Ozakbas S, Iuliano G, Boz C, Hupperts R, Grand’Maison F, Oreja-Guevara C, van Pesch V, Cartechini E, Petersen T, Altintas A, Soysal A, Ramo-Tello C, McCombe P, Turkoglu R, Butzkueven H, Wolinsky JS, Solaro C, Sormani MP.Neurology. 2021 Jan 12;96(2):e214-e227. doi: 10.1212/WNL.0000000000010991. Epub 2020 Oct 6.PMID: 33024022
 
 

Delay from treatment start to full effect of immunotherapies for multiple sclerosis.

Roos I, Leray E, Frascoli F, Casey R, Brown JWL, Horakova D, Havrdova EK, Trojano M, Patti F, Izquierdo G, Eichau S, Onofrj M, Lugaresi A, Prat A, Girard M, Grammond P, Sola P, Ferraro D, Ozakbas S, Bergamaschi R, Sá MJ, Cartechini E, Boz C, Granella F, Hupperts R, Terzi M, Lechner-Scott J, Spitaleri D, Van Pesch V, Soysal A, Olascoaga J, Prevost J, Aguera-Morales E, Slee M, Csepany T, Turkoglu R, Sidhom Y, Gouider R, Van Wijmeersch B, McCombe P, Macdonell R, Coles A, Malpas CB, Butzkueven H, Vukusic S, Kalincik T; MSBase; OFSEP investigators.Brain. 2020 Sep 1;143(9):2742-2756. doi: 10.1093/brain/awaa231.PMID: 32947619
 

Ofatumumab versus Teriflunomide in Multiple Sclerosis.

Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups.N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246.PMID: 32757523 Clinical Trial.
 
 

Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis.

Lizak N, Malpas CB, Sharmin S, Havrdova EK, Horakova D, Izquierdo G, Eichau S, Lugaresi A, Duquette P, Girard M, Prat A, Larochelle C, Trojano M, Grand’Maison F, Grammond P, Sola P, Ferraro D, Hupperts R, Bergamaschi R, Boz C, Van Pesch V, Spitaleri D, Terzi M, Kalincik T; MSBase Study Group.JAMA Neurol. 2020 Jul 27;77(11):1-11. doi: 10.1001/jamaneurol.2020.2453. Online ahead of print.PMID: 32716480
 
 

Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score.

Kunchok A, Lechner-Scott J, Granella F, Trojano M, Alroughani R, Sola P, Ferraro D, Lugaresi A, Onofrj M, Ozakbas S, Izquierdo G, Grammond P, Luis Sanchez-Menoyo J, Van Wijmeersch B, Boz C, Pucci E, McCombe P, Grand’Maison F, Spitaleri D, Vucic S, Hupperts R, Jokubaitis V, Sormani MP, Butzkueven H, Kalincik T; MSBase Study Group.Mult Scler. 2020 Jul 8:1352458520936823. doi: 10.1177/1352458520936823. Online ahead of print.PMID: 32639855
 
 

Revisiting the complex architecture of ALS in Turkey: Expanding genotypes, shared phenotypes, molecular networks, and a public variant database.

Tunca C, Şeker T, Akçimen F, Coşkun C, Bayraktar E, Palvadeau R, Zor S, Koçoğlu C, Kartal E, Şen NE, Hamzeiy H, Özoğuz Erimiş A, Norman U, Karakahya O, Olgun G, Akgün T, Durmuş H, Şahin E, Çakar A, Başar Gürsoy E, Babacan Yıldız G, İşak B, Uluç K, Hanağası H, Bilgiç B, Turgut N, Aysal F, Ertaş M, Boz C, Kotan D, İdrisoğlu H, Soysal A, Uzun Adatepe N, Akalın MA, Koç F, Tan E, Oflazer P, Deymeer F, Taştan Ö, Çiçek AE, Kavak E, Parman Y, Başak AN.Hum Mutat. 2020 Aug;41(8):e7-e45. doi: 10.1002/humu.24055. Epub 2020 Jun 24.PMID: 32579787
 
 
Page 2

Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis.

Le M, Malpas C, Sharmin S, Horáková D, Havrdova E, Trojano M, Izquierdo G, Eichau S, Ozakbas S, Lugaresi A, Prat A, Girard M, Duquette P, Larochelle C, Alroughani R, Bergamaschi R, Sola P, Ferraro D, Grammond P, Grand’ Maison F, Terzi M, Boz C, Hupperts R, Butzkueven H, Pucci E, Granella F, Van Pesch V, Soysal A, Yamout BI, Lechner-Scott J, Spitaleri D, Ampapa R, Turkoglu R, Iuliano G, Ramo-Tello C, Sanchez-Menoyo JL, Sidhom Y, Gouider R, Shaygannejad V, Prevost J, Altintas A, Fragoso YD, McCombe PA, Petersen T, Slee M, Barnett MH, Vucic S, Van Der Walt A, Kalincik T.Mult Scler. 2020 Jun 15:1352458520926955. doi: 10.1177/1352458520926955. Online ahead of print.PMID: 32538713
 
 

Early clinical markers of aggressive multiple sclerosis.

Malpas CB, Manouchehrinia A, Sharmin S, Roos I, Horakova D, Havrdova EK, Trojano M, Izquierdo G, Eichau S, Bergamaschi R, Sola P, Ferraro D, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Grand’Maison F, Ozakbas S, Van Pesch V, Granella F, Hupperts R, Pucci E, Boz C, Sidhom Y, Gouider R, Spitaleri D, Soysal A, Petersen T, Verheul F, Karabudak R, Turkoglu R, Ramo-Tello C, Terzi M, Cristiano E, Slee M, McCombe P, Macdonell R, Fragoso Y, Olascoaga J, Altintas A, Olsson T, Butzkueven H, Hillert J, Kalincik T.Brain. 2020 May 1;143(5):1400-1413. doi: 10.1093/brain/awaa081.PMID: 32386427
 
 

1.Electrophysiological, functional and histopathological assessments of high dose melatonin on regeneration after blunt sciatic nerve injury. Yazar U, Çakır E, Boz C, Çobanoğlu Ü, Baykal S. J Clin Neurosci. 2020 Jan 14. pii: S0967-5868(19)31841-7. doi: 10.1016/j.jocn.2020.01.006. [Epub ahead of print]

2. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. Kunchok A, Malpas C, Nytrova P, Havrdova EK, Alroughani R, Terzi M, Yamout B, Hor JY, Karabudak R, Boz C, Ozakbas S, Olascoaga J, Simo M, Granella F, Patti F, McCombe P, Csepany T, Singhal B, Bergamaschi R, Fragoso Y, Al-Harbi T, Turkoglu R, Lechner-Scott J, Laureys G, Oreja-Guevara C, Pucci E, Sola P, Ferraro D, Altintas A, Soysal A, Vucic S, Grand’Maison F, Izquierdo G, Eichau S, Lugaresi A, Onofrj M, Trojano M, Marriott M, Butzkueven H, Kister I, Kalincik T. Mult Scler Relat Disord. 2019 Nov 25;38:101868. doi: 10.1016/j.msard.2019.101868. [Epub ahead of print]
 
3. Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis. Boz C, Terzi M, Özer B, Turkoglu R, Karabudak R, Efendi H, Soysal A, Sevim S, Altintas A, Kurne A, Akçalı A, Akman G, Yüceyar N, Balcı BP, Ekmekci Ö, Karahan SZ, Demirkıran M, Altunrende B, Turan ÖF, Gökçen GözübatıkÇelik, Kale N, Köseoğlu M, Ozakbas S Mult Scler Relat Disord. 2019 Nov;36:101376. doi: 10.1016/j.msard.2019.101376. Epub 2019 Aug 26.
4. Risk of secondary progressive multiple sclerosis: A longitudinal study. Fambiatos A, Jokubaitis V, Horakova D, Kubala Havrdova E, Trojano M, Prat A, Girard M, Duquette P, Lugaresi A, Izquierdo G, Grand’Maison F, Grammond P, Sola P, Ferraro D, Alroughani R, Terzi M, Hupperts R, Boz C, Lechner-Scott J, Pucci E, Bergamaschi R, Van Pesch V, Ozakbas S, Granella F, Turkoglu R, Iuliano G, Spitaleri D, McCombe P, Solaro C, Slee M, Ampapa R, Soysal A, Petersen T, Sanchez-Menoyo JL, Verheul F, Prevost J, Sidhom Y, Van Wijmeersch B, Vucic S, Cristiano E, Saladino ML, Deri N, Barnett M, Olascoaga J, Moore F, Skibina O, Gray O, Fragoso Y, Yamout B, Shaw C, Singhal B, Shuey N, Hodgkinson S, Altintas A, Al-Harbi T, Csepany T, Taylor B, Hughes J, Jun JK, van der Walt A, Spelman T, Butzkueven H, Kalincik T. Mult Scler. 2020 Jan;26(1):79-90. doi: 10.1177/1352458519868990. Epub 2019 Aug 9.
 
 
6. Susac Syndrome: Clinical characteristics, diagnostic findings and treatment in 19 cases. Zengin Karahan S, Boz C, Saip S, Kale N, Demirkaya S, Celik Y, Demir S, Kurne A, Ozbek SE, Terzi M. Mult Scler Relat Disord. 2019 Aug;33:94-99. doi: 10.1016/j.msard.2019.05.018. 7. The Efficacy of Acupuncture in the Treatment of Bell’s Palsy Sequelae. Öksüz CE, Kalaycıoğlu A, Uzun Ö, Kalkışım ŞN, Zihni NB, Yıldırım A, Boz CJ Acupunct Meridian Stud. 2019 Aug;12(4):122-130. doi: 10.1016/j.jams.2019.03.001. Epub 2019 Apr 1.
 
8. Erratum: Evaluating Treatment Decision for Multiple Sclerosis: Real Life and Patient Experiences. Efendi H, Boz C, Karabudak R. Noro Psikiyatr Ars. 2019 Mar;56(1):82. doi: 10.29399/npa.23599.
9. Evaluating Treatment Decision for Multiple Sclerosis: Real Life and Patient Experiences. Efendi H, Boz C, Karabudak R. Noro Psikiyatr Ars. 2018;55(Suppl 1):S10-S14. doi: 10.29399/npa.23164. Review. Erratum in: Noro Psikiyatr Ars. 2019 Mar;56(1):82.
10. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. Kalincik T, Kubala Havrdova E, Horakova D, Izquierdo G, Prat A, Girard M, Duquette P, Grammond P, Onofrj M, Lugaresi A, Ozakbas S, Kappos L, Kuhle J, Terzi M, Lechner-Scott J, Boz C, Grand’Maison F, Prevost J, Sola P, Ferraro D, Granella F, Trojano M, Bergamaschi R, Pucci E, Turkoglu R, McCombe PA, Pesch VV, Van Wijmeersch B, Solaro C, Ramo-Tello C, Slee M, Alroughani R, Yamout B, Shaygannejad V, Spitaleri D, Sánchez-Menoyo JL, Ampapa R, Hodgkinson S, Karabudak R, Butler E, Vucic S, Jokubaitis V, Spelman T, Butzkueven H. J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):458-468. doi: 10.1136/jnnp-2018-319831. Epub 2019 Jan 13.
 
11. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. Nguyen AL, Havrdova EK, Horakova D, Izquierdo G, Kalincik T, van der Walt A, Terzi M, Alroughani R, Duquette P, Girard M, Prat A, Boz C, Sola P, Ferraro D, Lugaresi A, Lechner-Scott J, Barnett M, Grand’Maison F, Grammond P, Ramo-Tello C, Turkoglu R, McCombe P, Pucci E, Trojano M, Granella F, Spitaleri D, Van Pesch V, Soysal A, Oreja-Guevara C, Verheul F, Vucic S, Hodgkinson S, Slee M, Ampapa R, Prevost J, Menoyo JLS, Skibina O, Solaro C, Olascoaga J, Shaw C, Madsen KG, Naidoo K, Hyde R, Butzkueven H, Jokubaitis V; MSBase Study Group. Mult Scler Relat Disord. 2019 Feb;28:235-243. doi: 10.1016/j.msard.2019.01.003. Epub 2019 Jan 3.
 
12. International consensus on quality standards for brain health-focused care in multiple sclerosis. Hobart J, Bowen A, Pepper G, Crofts H, Eberhard L, Berger T, Boyko A, Boz C, Butzkueven H, Celius EG, Drulovic J, Flores J, Horáková D, Lebrun-Frénay C, Marrie RA, Overell J, Piehl F, Rasmussen PV, Sá MJ, Sîrbu CA, Skromne E, Torkildsen Ø, van Pesch V, Vollmer T, Zakaria M, Ziemssen T, Giovannoni G. Mult Scler. 2019 Nov;25(13):1809-1818. doi: 10.1177/1352458518809326. Epub 2018 Nov 1.
 
13. Silent lesions on MRI imaging – Shifting goal posts for treatment decisions in multiple sclerosis. Min M, Spelman T, Lugaresi A, Boz C, Spitaleri D, Pucci E, Grand’Maison F, Granella F, Izquierdo G, Butzkueven H, Sanchez-Menoyo JL, Barnett M, Girard M, Trojano M, Grammond P, Duquette P, Sola P, Alroughani R, Hupperts R, Vucic S, Kalincik T, Van Pesch V, Lechner-Scott J. Mult Scler. 2018 Oct;24(12):1569-1577. doi: 10.1177/1352458518798147. Epub 2018 Sep 14. Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. Kister I, Spelman T, Patti F, Duquette P, Trojano M, Izquierdo G, Lugaresi A, Grammond P, Sola P, Ferraro D, Grand’Maison F, Alroughani R, Terzi M, Boz C, Hupperts R, Lechner-Scott J, Kappos L, Pucci E, Hodgkinson S, Solaro C, Butzkueven H. J Neurol Sci. 2018 Aug 15;391:72-76. doi: 10.1016/j.jns.2018.06.001. Epub 2018 Jun 2.
 
15.

Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.

Hughes J, Jokubaitis V, Lugaresi A, Hupperts R, Izquierdo G, Prat A, Girard M, Duquette P, Grand’Maison F, Grammond P, Sola P, Ferraro D, Ramo-Tello C, Trojano M, Slee M, Shaygannejad V, Boz C, Lechner-Scott J, Van Pesch V, Pucci E, Solaro C, Verheul F, Terzi M, Granella F, Spitaleri D, Alroughani R, Jun JK, Fambiatos A, Van der Walt A, Butzkueven H, Kalincik T; MSBase Study Group.

JAMA Neurol. 2018 Nov 1;75(11):1407-1415. doi: 10.1001/jamaneurol.2018.2109.

 
16.

Reply to: Comment on Y.D. Fragoso et al.: “Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod” [Mult. Scler. Relat. Disord. (2017)].

Fragoso YD, Spelman T, Boz C, Alroughani R, Lugaresi A, Vucic S, Butzkueven H, Terzi M, Havrdova E, Horakova D, Granella F, Olascoaga J, Menoyo JLS, Pucci E, Barnett M, Brooks JBB, Haartsen J; Lymphopenia and Efficacy of Fingolimod MSBase sub-study Investigators.

Mult Scler Relat Disord. 2018 May;22:166. doi: 10.1016/j.msard.2018.02.025. Epub 2018 Feb 24. No abstract available.

 
17.

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators.

Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23. Erratum in: Lancet. 2018 Nov 17;392(10160):2170.

 
18.

Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod.

Fragoso YD, Spelman T, Boz C, Alroughani R, Lugaresi A, Vucic S, Butzkueven H, Terzi M, Havrdova E, Horakova D, Granella F, Olascoaga J, Sánchez-Menoyo JL, Pucci E, Barnett M, Brooks JBB, Haartsen J; Lymphopenia and Efficacy of Fingolimod MSBase sub-study Investigators.

Mult Scler Relat Disord. 2018 Jan;19:105-108. doi: 10.1016/j.msard.2017.11.018. Epub 2017 Nov 22.

 
19.

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.

Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O’Brien F, Wang JJ, Mantegazza R; REGAIN Study Group.

Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20. Erratum in: Lancet Neurol. 2017 Dec;16(12 ):954.

PMID:
29066163
20.

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.

Kalincik T, Manouchehrinia A, Sobisek L, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Girard M, Prat A, Duquette P, Grammond P, Sola P, Hupperts R, Grand’Maison F, Pucci E, Boz C, Alroughani R, Van Pesch V, Lechner-Scott J, Terzi M, Bergamaschi R, Iuliano G, Granella F, Spitaleri D, Shaygannejad V, Oreja-Guevara C, Slee M, Ampapa R, Verheul F, McCombe P, Olascoaga J, Amato MP, Vucic S, Hodgkinson S, Ramo-Tello C, Flechter S, Cristiano E, Rozsa C, Moore F, Luis Sanchez-Menoyo J, Laura Saladino M, Barnett M, Hillert J, Butzkueven H; MSBase Study Group.

Brain. 2017 Sep 1;140(9):2426-2443. doi: 10.1093/brain/awx185.

PMID:
29050389
21.

Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.

Lorscheider J, Jokubaitis VG, Spelman T, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Trojano M, Duquette P, Girard M, Prat A, Grand’Maison F, Grammond P, Pucci E, Boz C, Sola P, Ferraro D, Spitaleri D, Lechner-Scott J, Terzi M, Van Pesch V, Iuliano G, Bergamaschi R, Ramo-Tello C, Granella F, Oreja-Guevara C, Butzkueven H, Kalincik T; MSBase Study Group.

Neurology. 2017 Sep 5;89(10):1050-1059. doi: 10.1212/WNL.0000000000004330. Epub 2017 Aug 9.

22.

Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis.

Boz C, Terzi M, Zengin Karahan S, Sen S, Sarac Y, Emrah Mavis M.

Mult Scler. 2018 Aug;24(9):1205-1211. doi: 10.1177/1352458517717806. Epub 2017 Jun 26.

PMID:
28649909
23.

A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients – FINE Trial.

Demır GA, Türkoğlu R, Saıp S, Yüceyar N, Efendı H, Turan ÖF, Ağan K, Terzı M, Boz C, Tuncer A, Koçer B, Kasap M, Çalişkan Z; Fine Study Group.

Noro Psikiyatr Ars. 2017 Jun 22;56(4):253-257. doi: 10.5152/npa.2017.20515. eCollection 2019 Dec.

24.

Prognostic indicators in pediatric clinically isolated syndrome.

Iaffaldano P, Simone M, Lucisano G, Ghezzi A, Coniglio G, Brescia Morra V, Salemi G, Patti F, Lugaresi A, Izquierdo G, Bergamaschi R, Cabrera-Gomez JA, Pozzilli C, Millefiorini E, Alroughani R, Boz C, Pucci E, Zimatore GB, Sola P, Lus G, Maimone D, Avolio C, Cocco E, Sajedi SA, Costantino G, Duquette P, Shaygannejad V, Petersen T, Fernández Bolaños R, Paolicelli D, Tortorella C, Spelman T, Margari L, Amato MP, Comi G, Butzkueven H, Trojano M; Italian iMedWeb Registry and the MSBase Registry.

Ann Neurol. 2017 May;81(5):729-739. doi: 10.1002/ana.24938.

PMID:
28439957
25.

Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.

Signori A, Izquierdo G, Lugaresi A, Hupperts R, Grand’Maison F, Sola P, Horakova D, Havrdova E, Prat A, Girard M, Duquette P, Boz C, Grammond P, Terzi M, Singhal B, Alroughani R, Petersen T, Ramo C, Oreja-Guevara C, Spitaleri D, Shaygannejad V, Butzkueven H, Kalincik T, Jokubaitis V, Slee M, Fernandez Bolaños R, Sanchez-Menoyo JL, Pucci E, Granella F, Lechner-Scott J, Iuliano G, Hughes S, Bergamaschi R, Taylor B, Verheul F, Edite Rio M, Amato MP, Sajedi SA, Majdinasab N, Van Pesch V, Sormani MP, Trojano M.

Mult Scler. 2018 Apr;24(5):642-652. doi: 10.1177/1352458517703800. Epub 2017 Apr 6.

PMID:
28382837
26.

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.

Kalincik T, Brown JWL, Robertson N, Willis M, Scolding N, Rice CM, Wilkins A, Pearson O, Ziemssen T, Hutchinson M, McGuigan C, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Alroughani R, Pucci E, Sola P, Hupperts R, Lechner-Scott J, Terzi M, Van Pesch V, Rozsa C, Grand’Maison F, Boz C, Granella F, Slee M, Spitaleri D, Olascoaga J, Bergamaschi R, Verheul F, Vucic S, McCombe P, Hodgkinson S, Sanchez-Menoyo JL, Ampapa R, Simo M, Csepany T, Ramo C, Cristiano E, Barnett M, Butzkueven H, Coles A; MSBase Study Group.

Lancet Neurol. 2017 Apr;16(4):271-281. doi: 10.1016/S1474-4422(17)30007-8. Epub 2017 Feb 11.

PMID:
28209331
27.

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.

28.

Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice.

Spelman T, Meyniel C, Rojas JI, Lugaresi A, Izquierdo G, Grand’Maison F, Boz C, Alroughani R, Havrdova E, Horakova D, Iuliano G, Duquette P, Terzi M, Grammond P, Hupperts R, Lechner-Scott J, Oreja-Guevara C, Pucci E, Verheul F, Fiol M, Van Pesch V, Cristiano E, Petersen T, Moore F, Kalincik T, Jokubaitis V, Trojano M, Butzkueven H; MSBasis (an MSBase Substudy) Investigators.

Mult Scler. 2017 Sep;23(10):1346-1357. doi: 10.1177/1352458516679893. Epub 2016 Nov 25.

PMID:
27885062
29.

Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis.

Lizak N, Lugaresi A, Alroughani R, Lechner-Scott J, Slee M, Havrdova E, Horakova D, Trojano M, Izquierdo G, Duquette P, Girard M, Prat A, Grammond P, Hupperts R, Grand’Maison F, Sola P, Pucci E, Bergamaschi R, Oreja-Guevara C, Van Pesch V, Ramo C, Spitaleri D, Iuliano G, Boz C, Granella F, Olascoaga J, Verheul F, Rozsa C, Cristiano E, Flechter S, Hodgkinson S, Amato MP, Deri N, Jokubaitis V, Spelman T, Butzkueven H, Kalincik T; MSBase Study Group.

J Neurol Neurosurg Psychiatry. 2017 Mar;88(3):196-203. doi: 10.1136/jnnp-2016-313976. Epub 2016 Sep 28.

PMID:
27683916
30.

Defining secondary progressive multiple sclerosis.

Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P, Prat A, Lugaresi A, Grand’Maison F, Grammond P, Hupperts R, Alroughani R, Sola P, Boz C, Pucci E, Lechner-Scott J, Bergamaschi R, Oreja-Guevara C, Iuliano G, Van Pesch V, Granella F, Ramo-Tello C, Spitaleri D, Petersen T, Slee M, Verheul F, Ampapa R, Amato MP, McCombe P, Vucic S, Sánchez Menoyo JL, Cristiano E, Barnett MH, Hodgkinson S, Olascoaga J, Saladino ML, Gray O, Shaw C, Moore F, Butzkueven H, Kalincik T; MSBase Study Group.

Brain. 2016 Sep;139(Pt 9):2395-405. doi: 10.1093/brain/aww173. Epub 2016 Jul 7.

PMID:
27401521
31.

Predictors of long-term disability accrual in relapse-onset multiple sclerosis.

Jokubaitis VG, Spelman T, Kalincik T, Lorscheider J, Havrdova E, Horakova D, Duquette P, Girard M, Prat A, Izquierdo G, Grammond P, Van Pesch V, Pucci E, Grand’Maison F, Hupperts R, Granella F, Sola P, Bergamaschi R, Iuliano G, Spitaleri D, Boz C, Hodgkinson S, Olascoaga J, Verheul F, McCombe P, Petersen T, Rozsa C, Lechner-Scott J, Saladino ML, Farina D, Iaffaldano P, Paolicelli D, Butzkueven H, Lugaresi A, Trojano M; MSBase Study Group.

Ann Neurol. 2016 Jul;80(1):89-100. doi: 10.1002/ana.24682. Epub 2016 Jun 1.

PMID:
27145331
32.

Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.

Spelman T, Kalincik T, Jokubaitis V, Zhang A, Pellegrini F, Wiendl H, Belachew S, Hyde R, Verheul F, Lugaresi A, Havrdová E, Horáková D, Grammond P, Duquette P, Prat A, Iuliano G, Terzi M, Izquierdo G, Hupperts RM, Boz C, Pucci E, Giuliani G, Sola P, Spitaleri DL, Lechner-Scott J, Bergamaschi R, Grand’Maison F, Granella F, Kappos L, Trojano M, Butzkueven H.

Neurol Clin Pract. 2016 Apr;6(2):102-115.

33.

Contribution of different relapse phenotypes to disability in multiple sclerosis.

Stewart T, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Duquette P, Girard M, Prat A, Lugaresi A, Grand’Maison F, Grammond P, Sola P, Shaygannejad V, Hupperts R, Alroughani R, Oreja-Guevara C, Pucci E, Boz C, Lechner-Scott J, Bergamaschi R, Van Pesch V, Iuliano G, Ramo C, Taylor B, Slee M, Spitaleri D, Granella F, Verheul F, McCombe P, Hodgkinson S, Amato MP, Vucic S, Gray O, Cristiano E, Barnett M, Sanchez Menoyo JL, van Munster E, Saladino ML, Olascoaga J, Prevost J, Deri N, Shaw C, Singhal B, Moore F, Rozsa C, Shuey N, Skibina O, Kister I, Petkovska-Boskova T, Ampapa R, Kermode A, Butzkueven H, Jokubaitis V, Kalincik T; MSBase Study Group.

Mult Scler. 2017 Feb;23(2):266-276. doi: 10.1177/1352458516643392. Epub 2016 Jul 11.

PMID:
27055805
34.

Lack of Association between Pulse Steroid Therapy and Bone Mineral Density in Patients with Multiple Sclerosis.

Zengin Karahan S, Boz C, Kilic S, Can Usta N, Ozmenoglu M, Altunayoglu Cakmak V, Gazioglu S.

Mult Scler Int. 2016;2016:5794910. doi: 10.1155/2016/5794910. Epub 2016 Feb 4.

35.

Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort: Demographic, Clinical, and Laboratory Features.

Altintas A, Karabudak R, Balci BP, Terzi M, Soysal A, Saip S, Tuncer Kurne A, Uygunoglu U, Nalbantoglu M, Gozubatik Celik G, Isik N, Celik Y, Gokcay F, Duman T, Boz C, Yucesan C, Mangan MS, Celebisoy N, Diker S, Colpak Isikay I, Kansu T, Siva A.

Neurologist. 2015 Oct;20(4):61-6. doi: 10.1097/NRL.0000000000000057.

PMID:
26468870
36.

Defining reliable disability outcomes in multiple sclerosis.

Kalincik T, Cutter G, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P, Prat A, Lugaresi A, Grand’Maison F, Grammond P, Hupperts R, Oreja-Guevara C, Boz C, Pucci E, Bergamaschi R, Lechner-Scott J, Alroughani R, Van Pesch V, Iuliano G, Fernandez-Bolaños R, Ramo C, Terzi M, Slee M, Spitaleri D, Verheul F, Cristiano E, Sánchez-Menoyo JL, Fiol M, Gray O, Cabrera-Gomez JA, Barnett M, Butzkueven H.

Brain. 2015 Nov;138(Pt 11):3287-98. doi: 10.1093/brain/awv258. Epub 2015 Sep 10.

PMID:
26359291
37.

Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry.

Rojas JI, Patrucco L, Trojano M, Lugaresi A, Izquierdo G, Butzkueven H, Jokubaitis V, Duquette P, Girard M, Grand’Maison F, Grammond P, Oreja-Guevara C, Hupperts R, Boz C, Petersen T, Bergamaschi R, Giuliani G, Lechner-Scott J, Barnett M, Rio ME, Van Pesch V, Amato MP, Iuliano G, Fiol M, Slee M, Verheul F, Fernandez-Bolanos R, Poehlau D, Saladino ML, Braber-Moerland LD, Deri N, Oleschko-Arruda W, Cabrera-Gomez JA, Paine M, Vella N, Kister I, Skromne E, Savino A, Shaw C, Moore F, Vucic S, Petkovska-Boskova T, Bacile EAB, Santiago V, Cristiano E.

Mult Scler J Exp Transl Clin. 2015 Aug 17;1:2055217315600193. doi: 10.1177/2055217315600193. eCollection 2015 Jan-Dec.

38.

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.

Warrender-Sparkes M, Spelman T, Izquierdo G, Trojano M, Lugaresi A, Grand’Maison F, Havrdova E, Horakova D, Boz C, Oreja-Guevara C, Alroughani R, Iuliano G, Duquette P, Girard M, Terzi M, Hupperts R, Grammond P, Petersen T, Fernandez-Bolaños R, Fiol M, Pucci E, Lechner-Scott J, Verheul F, Cristiano E, Van Pesch V, Petkovska-Boskova T, Moore F, Kister I, Bergamaschi R, Saladino ML, Slee M, Barnett M, Amato MP, Shaw C, Shuey N, Young C, Gray O, Kappos L, Butzkueven H, Kalincik T, Jokubaitis V; MSBase study group.

Mult Scler. 2016 Apr;22(4):520-32. doi: 10.1177/1352458515594041. Epub 2015 Jul 21.

PMID:
26199347
39.

Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS.

Ribbons KA, McElduff P, Boz C, Trojano M, Izquierdo G, Duquette P, Girard M, Grand’Maison F, Hupperts R, Grammond P, Oreja-Guevara C, Petersen T, Bergamaschi R, Giuliani G, Barnett M, van Pesch V, Amato MP, Iuliano G, Fiol M, Slee M, Verheul F, Cristiano E, Fernandez-Bolanos R, Saladino ML, Rio ME, Cabrera-Gomez J, Butzkueven H, van Munster E, Den Braber-Moerland L, La Spitaleri D, Lugaresi A, Shaygannejad V, Gray O, Deri N, Alroughani R, Lechner-Scott J.

PLoS One. 2015 Jun 5;10(6):e0122686. doi: 10.1371/journal.pone.0122686. eCollection 2015.

40.

Predictors of disability worsening in clinically isolated syndrome.

Jokubaitis VG, Spelman T, Kalincik T, Izquierdo G, Grand’Maison F, Duquette P, Girard M, Lugaresi A, Grammond P, Hupperts R, Cabrera-Gomez J, Oreja-Guevara C, Boz C, Giuliani G, Fernández-Bolaños R, Iuliano G, Lechner-Scott J, Verheul F, van Pesch V, Petkovska-Boskova T, Fiol M, Moore F, Cristiano E, Alroughani R, Bergamaschi R, Barnett M, Slee M, Vella N, Herbert J, Shaw C, Saladino ML, Amato MP, Liew D, Paolicelli D, Butzkueven H, Trojano M.

Ann Clin Transl Neurol. 2015 May;2(5):479-91. doi: 10.1002/acn3.187. Epub 2015 Mar 27.

41.

BREMSO: a simple score to predict early the natural course of multiple sclerosis.

Bergamaschi R, Montomoli C, Mallucci G, Lugaresi A, Izquierdo G, Grand’Maison F, Duquette P, Shaygannejad V, Alroughani R, Grammond P, Boz C, Iuliano G, Zwanikken C, Petersen T, Lechner-Scott J, Hupperts R, Butzkueven H, Pucci E, Oreja-Guevara C, Cristiano E, Pia Amato MP, Havrdova E, Fernandez-Bolanos R, Spelman T, Trojano M.

Eur J Neurol. 2015 Jun;22(6):981-9. doi: 10.1111/ene.12696. Epub 2015 Mar 25.

PMID:
25808578
42.

Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.

He A, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Girard M, Pucci E, Iuliano G, Alroughani R, Oreja-Guevara C, Fernandez-Bolaños R, Grand’Maison F, Sola P, Spitaleri D, Granella F, Terzi M, Lechner-Scott J, Van Pesch V, Hupperts R, Sánchez-Menoyo JL, Hodgkinson S, Rozsa C, Verheul F, Butzkueven H, Kalincik T; MSBase Study Group.

JAMA Neurol. 2015 Apr;72(4):405-13. doi: 10.1001/jamaneurol.2014.4147. Erratum in: JAMA Neurol. 2015 Aug;72(8):950.

43.

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.

Kalincik T, Horakova D, Spelman T, Jokubaitis V, Trojano M, Lugaresi A, Izquierdo G, Rozsa C, Grammond P, Alroughani R, Duquette P, Girard M, Pucci E, Lechner-Scott J, Slee M, Fernandez-Bolanos R, Grand’Maison F, Hupperts R, Verheul F, Hodgkinson S, Oreja-Guevara C, Spitaleri D, Barnett M, Terzi M, Bergamaschi R, McCombe P, Sanchez-Menoyo J, Simo M, Csepany T, Rum G, Boz C, Havrdova E, Butzkueven H; MSBase Study Group.

Ann Neurol. 2015 Mar;77(3):425-35. doi: 10.1002/ana.24339. Epub 2015 Jan 17.

PMID:
25546031
44.

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis.

Kalincik T, Jokubaitis V, Izquierdo G, Duquette P, Girard M, Grammond P, Lugaresi A, Oreja-Guevara C, Bergamaschi R, Hupperts R, Grand’Maison F, Pucci E, Van Pesch V, Boz C, Iuliano G, Fernandez-Bolanos R, Flechter S, Spitaleri D, Cristiano E, Verheul F, Lechner-Scott J, Amato MP, Cabrera-Gomez JA, Saladino ML, Slee M, Moore F, Gray O, Paine M, Barnett M, Havrdova E, Horakova D, Spelman T, Trojano M, Butzkueven H; MSBase Study Group.

Mult Scler. 2015 Aug;21(9):1159-71. doi: 10.1177/1352458514559865. Epub 2014 Dec 5.

PMID:
25480857
45.

Evaluation of temperament and character features as risk factors for depressive symptoms in patients with restless legs syndrome.

Altunayoglu Cakmak V, Gazioglu S, Can Usta N, Ozkorumak E, Ayar A, Topbas M, Boz C.

J Clin Neurol. 2014 Oct;10(4):320-7. doi: 10.3988/jcn.2014.10.4.320. Epub 2014 Oct 6.

46.

Seasonal variation of relapse rate in multiple sclerosis is latitude dependent.

Spelman T, Gray O, Trojano M, Petersen T, Izquierdo G, Lugaresi A, Hupperts R, Bergamaschi R, Duquette P, Grammond P, Giuliani G, Boz C, Verheul F, Oreja-Guevara C, Barnett M, Grand’Maison F, Edite Rio M, Lechner-Scott J, Van Pesch V, Fernandez Bolanos R, Flechter S, Den Braber-Moerland L, Iuliano G, Amato MP, Slee M, Cristiano E, Saladino ML, Paine M, Vella N, Kasa K, Deri N, Herbert J, Moore F, Petkovska-Boskova T, Alroughani R, Savino A, Shaw C, Vucic S, Santiago V, Bacile EA, Skromne E, Poehlau D, Cabrera-Gomez JA, Lucas R, Butzkueven H.

Ann Neurol. 2014 Dec;76(6):880-90. doi: 10.1002/ana.24287. Epub 2014 Oct 20.

PMID:
25283272
47.

Risk of relapse phenotype recurrence in multiple sclerosis.

Kalincik T, Buzzard K, Jokubaitis V, Trojano M, Duquette P, Izquierdo G, Girard M, Lugaresi A, Grammond P, Grand’Maison F, Oreja-Guevara C, Boz C, Hupperts R, Petersen T, Giuliani G, Iuliano G, Lechner-Scott J, Barnett M, Bergamaschi R, Van Pesch V, Amato MP, van Munster E, Fernandez-Bolanos R, Verheul F, Fiol M, Cristiano E, Slee M, Rio ME, Spitaleri D, Alroughani R, Gray O, Saladino ML, Flechter S, Herbert J, Cabrera-Gomez JA, Vella N, Paine M, Shaw C, Moore F, Vucic S, Savino A, Singhal B, Petkovska-Boskova T, Parratt J, Sirbu CA, Rozsa C, Liew D, Butzkueven H; MSBase Study Group.

Mult Scler. 2014 Oct;20(11):1511-22. doi: 10.1177/1352458514528762. Epub 2014 Apr 28.

PMID:
24777276
48.

Factors associated with early hospital arrival in acute ischemic stroke patients.

Koksal EK, Gazioglu S, Boz C, Can G, Alioglu Z.

Neurol Sci. 2014 Oct;35(10):1567-72. doi: 10.1007/s10072-014-1796-3. Epub 2014 Apr 18.

PMID:
24744194
49.

Personality traits of patients with multiple sclerosis and their relationship with clinical characteristics.

Gazioglu S, Cakmak VA, Ozkorumak E, Usta NC, Ates C, Boz C.

J Nerv Ment Dis. 2014 May;202(5):408-11. doi: 10.1097/NMD.0000000000000114.

PMID:
24727727
50.

Fingolimod after natalizumab and the risk of short-term relapse.

Jokubaitis VG, Li V, Kalincik T, Izquierdo G, Hodgkinson S, Alroughani R, Lechner-Scott J, Lugaresi A, Duquette P, Girard M, Barnett M, Grand’Maison F, Trojano M, Slee M, Giuliani G, Shaw C, Boz C, Spitaleri DL, Verheul F, Haartsen J, Liew D, Butzkueven H; MSBase Study Group.

Neurology. 2014 Apr 8;82(14):1204-11. doi: 10.1212/WNL.0000000000000283. Epub 2014 Mar 7.

51.

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.

Confavreux C, O’Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L; TOWER Trial Group.

Lancet Neurol. 2014 Mar;13(3):247-56. doi: 10.1016/S1474-4422(13)70308-9. Epub 2014 Jan 23.

PMID:
24461574
52.

Sex as a determinant of relapse incidence and progressive course of multiple sclerosis.

Kalincik T, Vivek V, Jokubaitis V, Lechner-Scott J, Trojano M, Izquierdo G, Lugaresi A, Grand’maison F, Hupperts R, Oreja-Guevara C, Bergamaschi R, Iuliano G, Alroughani R, Van Pesch V, Amato MP, Slee M, Verheul F, Fernandez-Bolanos R, Fiol M, Spitaleri DL, Cristiano E, Gray O, Cabrera-Gomez JA, Shaygannejad V, Herbert J, Vucic S, Needham M, Petkovska-Boskova T, Sirbu CA, Duquette P, Girard M, Grammond P, Boz C, Giuliani G, Rio ME, Barnett M, Flechter S, Moore F, Singhal B, Bacile EA, Saladino ML, Shaw C, Skromne E, Poehlau D, Vella N, Spelman T, Liew D, Kilpatrick TJ, Butzkueven H; MSBase Study Group.

Brain. 2013 Dec;136(Pt 12):3609-17. doi: 10.1093/brain/awt281. Epub 2013 Oct 18.

PMID:
24142147
53.

Predictors and dynamics of postpartum relapses in women with multiple sclerosis.

Hughes SE, Spelman T, Gray OM, Boz C, Trojano M, Lugaresi A, Izquierdo G, Duquette P, Girard M, Grand’Maison F, Grammond P, Oreja-Guevara C, Hupperts R, Bergamaschi R, Giuliani G, Lechner-Scott J, Barnett M, Edite Rio M, van Pesch V, Amato MP, Iuliano G, Slee M, Verheul F, Cristiano E, Fernández-Bolaños R, Poehlau D, Saladino ML, Deri N, Cabrera-Gomez J, Vella N, Herbert J, Skromne E, Savino A, Shaw C, Moore F, Vucic S, Petkovska-Boskova T, McDonnell G, Hawkins S, Kee F, Butzkueven H; MSBase study group.

Mult Scler. 2014 May;20(6):739-46. doi: 10.1177/1352458513507816. Epub 2013 Oct 9.

PMID:
24107309
54.

Cerebral venous thrombosis after high dose steroid in multiple sclerosis: a case report.

Gazioglu S, Solmaz D, Boz C.

Hippokratia. 2013 Jan;17(1):88-90.

55.

Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis.

Kalincik T, Spelman T, Trojano M, Duquette P, Izquierdo G, Grammond P, Lugaresi A, Hupperts R, Cristiano E, Van Pesch V, Grand’maison F, La Spitaleri D, Rio ME, Flechter S, Oreja-Guevara C, Giuliani G, Savino A, Amato MP, Petersen T, Fernandez-Bolanos R, Bergamaschi R, Iuliano G, Boz C, Lechner-Scott J, Deri N, Gray O, Verheul F, Fiol M, Barnett M, van Munster E, Santiago V, Moore F, Slee M, Saladino ML, Alroughani R, Shaw C, Kasa K, Petkovska-Boskova T, den Braber-Moerland L, Chapman J, Skromne E, Herbert J, Poehlau D, Needham M, Bacile EA, Arruda WO, Paine M, Singhal B, Vucic S, Cabrera-Gomez JA, Butzkueven H; MSBase Study Group.

PLoS One. 2013 May 21;8(5):e63480. doi: 10.1371/journal.pone.0063480. Print 2013.

56.

Historical changes of seasonal differences in the frequency of multiple sclerosis clinical attacks: a multicenter study.

Iuliano G, Boz C, Cristiano E, Duquette P, Lugaresi A, Oreja-Guevara C, Van Pesch V.

J Neurol. 2013 May;260(5):1258-62. doi: 10.1007/s00415-012-6785-y. Epub 2012 Dec 21.

PMID:
23263474
57.

Geographical variations in sex ratio trends over time in multiple sclerosis.

Trojano M, Lucchese G, Graziano G, Taylor BV, Simpson S Jr, Lepore V, Grand’maison F, Duquette P, Izquierdo G, Grammond P, Amato MP, Bergamaschi R, Giuliani G, Boz C, Hupperts R, Van Pesch V, Lechner-Scott J, Cristiano E, Fiol M, Oreja-Guevara C, Saladino ML, Verheul F, Slee M, Paolicelli D, Tortorella C, D’Onghia M, Iaffaldano P, Direnzo V, Butzkueven H; MSBase Study Group and the New Zealand MS Prevalence Study Group.

PLoS One. 2012;7(10):e48078. doi: 10.1371/journal.pone.0048078. Epub 2012 Oct 25.

58.

Fluctuations of MS births and UV-light exposure.

Verheul F, Smolders J, Trojano M, Lepore V, Zwanikken C, Amato MP, Grand’maison F, Butzkueven H, Marrosu M, Duquette P, Comi G, Izquierdo G, Grammond P, Lus G, Petersen T, Bergamaschi R, Giuliani G, Boz C, Coniglio G, Van Pesch V, Lechner-Scott J, Cavalla P, Granella F, Avolio C, Fiol M, Poehlau D, Saladino ML, Gallo P, Deri N, Oleschko Arruda W, Paine M, Ferro M, Barnett M, Cabrera-Gomez JA, Slee M, Moore F, Shaw C, Petkovska-Boskova T, Rutherford M, Engelsen O, Damoiseaux J, Hupperts R.

Acta Neurol Scand. 2013 May;127(5):301-8. doi: 10.1111/ane.12007. Epub 2012 Sep 12.

PMID:
22970985
59.

Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome.

Meyniel C, Spelman T, Jokubaitis VG, Trojano M, Izquierdo G, Grand’Maison F, Oreja-Guevara C, Boz C, Lugaresi A, Girard M, Grammond P, Iuliano G, Fiol M, Cabrera-Gomez JA, Fernandez-Bolanos R, Giuliani G, Lechner-Scott J, Cristiano E, Herbert J, Petkovska-Boskova T, Bergamaschi R, van Pesch V, Moore F, Vella N, Slee M, Santiago V, Barnett M, Havrdova E, Young C, Sirbu CA, Tanner M, Rutherford M, Butzkueven H; MSBasis Study Group.

PLoS One. 2012;7(6):e38661. doi: 10.1371/journal.pone.0038661. Epub 2012 Jun 29.

60.

Increasing age at disability milestones among MS patients in the MSBase Registry.

Kister I, Chamot E, Cutter G, Bacon TE, Jokubaitis VG, Hughes SE, Gray OM, Trojano M, Izquierdo G, Grand’Maison F, Duquette P, Lugaresi A, Grammond P, Boz C, Hupperts R, Petersen T, Giuliani G, Oreja-Guevara C, Iuliano G, Lechner-Scott J, Bergamaschi R, Rio ME, Verheul F, Fiol M, Van Pesch V, Slee M, Butzkueven H, Herbert J; MSBase Investigators.

J Neurol Sci. 2012 Jul 15;318(1-2):94-9. doi: 10.1016/j.jns.2012.03.017. Epub 2012 Apr 14.

PMID:
22507751
61.

Cervical vestibular evoked myogenic potentials to air-conducted sound in early amyotrophic lateral sclerosis.

Kiliç S, Gazioglu S, Serap Zengin K, Ulkü Dübüş H, Boz C.

Neurophysiol Clin. 2012 Apr;42(3):119-23. doi: 10.1016/j.neucli.2012.01.001. Epub 2012 Jan 21.

PMID:
22500701
62.

Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study.

Altintas A, Petek B, Isik N, Terzi M, Bolukbasi F, Tavsanli M, Saip S, Boz C, Aydin T, Arici-Duz O, Ozer F, Siva A.

Mult Scler. 2012 Oct;18(10):1448-53. Epub 2012 Mar 14.

PMID:
22419670
63.

Ocular and cervical vestibular evoked myogenic potentials in multiple sclerosis patients.

Gazioglu S, Boz C.

Clin Neurophysiol. 2012 Sep;123(9):1872-9. doi: 10.1016/j.clinph.2012.01.022. Epub 2012 Mar 12.

PMID:
22418590
64.

The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry.

Hughes S, Spelman T, Trojano M, Lugaresi A, Izquierdo G, Grand’maison F, Duquette P, Girard M, Grammond P, Oreja-Guevara C, Hupperts R, Boz C, Bergamaschi R, Giuliani G, Rio ME, Lechner-Scott J, van Pesch V, Iuliano G, Fiol M, Verheul F, Barnett M, Slee M, Herbert J, Kister I, Vella N, Moore F, Petkovska-Boskova T, Shaygannejad V, Jokubaitis V, McDonnell G, Hawkins S, Kee F, Gray O, Butzkueven H; MSBase Study Group.

J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):305-10. doi: 10.1136/jnnp-2011-301051. Epub 2011 Dec 28.

PMID:
22205675
65.

The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude.

Lechner-Scott J, Spencer B, de Malmanche T, Attia J, Fitzgerald M, Trojano M, Grand’Maison F, Gomez JA, Izquierdo G, Duquette P, Girard M, Grammond P, Oreja-Guevara C, Hupperts R, Bergamaschi R, Boz C, Giuliani G, van Pesch V, Iuliano G, Fiol M, Cristiano E, Verheul F, Saladino ML, Slee M, Barnett M, Deri N, Flechter S, Vella N, Shaw C, Herbert J, Moore F, Petkovska-Boskova T, Jokubaitis V, Butzkueven H; MSBase study group.

Mult Scler. 2012 Jul;18(7):974-82. doi: 10.1177/1352458511431729. Epub 2011 Dec 20.

PMID:
22185806
66.

Magnetic resonance imaging in bilateral brachial neuritis with pure sensory involvement.

Gazioglu S, Boz C, Sarı A.

Neurol Sci. 2012 Aug;33(4):927-30. doi: 10.1007/s10072-011-0856-1. Epub 2011 Nov 24.

PMID:
22113229
67.

Basilar artery occlusion in migraine-like headache: a possible triggering effect of sumatriptan.

Gazioglu S, Boz C, Ozmenoglu M.

Neurol Sci. 2012 Feb;33(1):125-8. doi: 10.1007/s10072-011-0651-z. Epub 2011 Jun 17.

PMID:
21681368
68.

Electrodiagnosis of carpal tunnel syndrome in patients with diabetic polyneuropathy.

Gazioglu S, Boz C, Cakmak VA.

Clin Neurophysiol. 2011 Jul;122(7):1463-9. doi: 10.1016/j.clinph.2010.11.021. Epub 2011 Feb 16.

PMID:
21330198
69.

Prevalence of peripheral neuropathy and painful peripheral neuropathy in Turkish diabetic patients.

Erbas T, Ertas M, Yucel A, Keskinaslan A, Senocak M; TURNEP Study Group.

J Clin Neurophysiol. 2011 Feb;28(1):51-5. doi: 10.1097/WNP.0b013e3182051334.

PMID:
21221008
70.

VEMP responses are not affected in non-insulin-dependent diabetes mellitus patients with or without polyneuropathy.

Bektas D, Gazioglu S, Arslan S, Cobanoglu B, Boz C, Caylan R.

Acta Otolaryngol. 2008 Jul;128(7):768-71. doi: 10.1080/00016480701714251.

PMID:
18568519
71.

Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.

Boz C, Oger J, Gibbs E, Grossberg SE; Neurologists of the UBC MS Clinic.

Mult Scler. 2007 Nov;13(9):1127-37. Erratum in: Mult Scler. 2008 May;14(4):575.

PMID:
17967840
72.

Cerebral infarction following intravenous immunoglobulin therapy for Guillain-Barre syndrome.

Velioğlu SK, Ozmenoğlu M, Boz C.

J Stroke Cerebrovasc Dis. 2001 Nov-Dec;10(6):290-2.

PMID:
17903841
73.

Effect of serotonergic antidepressant therapy on temperament and character scales in patients with chronic tension-type headache.

Boz C, Gazioglu S, Altunayoglu V, Hocaoglu C.

Psychiatry Clin Neurosci. 2007 Oct;61(5):534-42.

74.

Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy.

Kister I, Gulati S, Boz C, Bergamaschi R, Piccolo G, Oger J, Swerdlow ML.

Arch Neurol. 2006 Jun;63(6):851-6. Erratum in: Arch Neurol. 2006 Sep;63(9):1342. Piccolo, Guiseppe [corrected to Piccolo, Giovanni].

PMID:
16769866
75.

Economic impact of primary headaches in Turkey: a university hospital based study: part II.

Karli N, Zarifoğlu M, Ertafş M, Saip S, Oztürk V, Biçakçi S, Boz C, Selçuki D, Oğuzhanoğlu A, Neyal M, Siva A, Irkeç C, Kaleağasi H, Kansu T, Sarica Y, Taşdemir N, Uzuner N.

J Headache Pain. 2006 Apr;7(2):75-82. Epub 2006 Mar 15.

76.

Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.

Boz C, Ozmenoglu M, Velioglu S, Kilinc K, Orem A, Alioglu Z, Altunayoglu V.

Clin Neurol Neurosurg. 2006 Feb;108(2):124-8.

PMID:
16412833
77.

The impact of migraine on epilepsy: a prospective prognosis study.

Velioğlu SK, Boz C, Ozmenoğlu M.

Cephalalgia. 2005 Jul;25(7):528-35.

PMID:
15955040
78.

Local cold effect on the excitability recovery curve of the sympathetic skin response.

Boz C, Ozmenoglu M, Alioglu Z, Velioglu S, Altunayoglu V, Gazioglu S.

Electromyogr Clin Neurophysiol. 2004 Dec;44(8):497-501.

PMID:
15646007
79.

The efficacy and safety of dipyrone (Novalgin) tablets in the treatment of acute migraine attacks: a double-blind, cross-over, randomized, placebo-controlled, multi-center study.

Tulunay FC, Ergün H, Gülmez SE, Ozbenli T, Ozmenoğlu M, Boz C, Erdemoglu AK, Varlikbas A, Göksan B, Inan L.

Funct Neurol. 2004 Jul-Sep;19(3):197-202.

PMID:
15595715
80.

Temperament and character profiles of patients with tension-type headache and migraine.

Boz C, Velioglu S, Ozmenoglu M, Sayar K, Alioglu Z, Yalman B, Topbas M.

Psychiatry Clin Neurosci. 2004 Oct;58(5):536-43.

81.

Transient tic disorder following carbon monoxide poisoning.

Alioglu Z, Boz C, Sari A, Aynaci M.

J Neuroradiol. 2004 Jun;31(3):231-3.

PMID:
15356451
82.

Individual risk factors for carpal tunnel syndrome: an evaluation of body mass index, wrist index and hand anthropometric measurements.

Boz C, Ozmenoglu M, Altunayoglu V, Velioglu S, Alioglu Z.

Clin Neurol Neurosurg. 2004 Sep;106(4):294-9.

PMID:
15297003
83.

[Temperament and character profile of patients with chronic tension-type headache].

Boz C, Sayar K, Velioğlu S, Hocaoğlu C, Alioğlu Z, Yalman B, Ozmenoğlu M.

Turk Psikiyatri Derg. 2004 Summer;15(2):105-11. Turkish.

84.

Benign acute childhood myositis.

Müjgan Sonmez F, Cakir M, Yayla S, Boz C.

Med Princ Pract. 2004 Jul-Aug;13(4):227-9.

85.

Guillain-Barré syndrome during treatment with interferon alpha for hepatitis B.

Boz C, Ozmenoglu M, Aktoz G, Velioglu S, Alioglu Z.

J Clin Neurosci. 2004 Jun;11(5):523-5.

PMID:
15177399
86.

Isolated hypoglossal nerve palsy in a child.

Aynaci EM, Sen Y, Boz C, Orhan F.

Turk J Pediatr. 2004 Jan-Mar;46(1):101-3.

PMID:
15074386
87.

Ocular myasthenia gravis associated with x-linked recessive spinal and bulbar muscular atrophy.

Boz C, Kalay E, Sahin N, Velioglu S, Ozmenoglu M, Karagüzel A.

J Clin Neuromuscul Dis. 2004 Mar;5(3):115-8.

PMID:
19078730
88.

Central nervous system involvement in autoimmune polyglandular syndrome.

Boz C, Velioglu S, Altunayoğlu V, Ozmenoglu M, Erem C.

Clin Neurol Neurosurg. 2003 Apr;105(2):102-4.

PMID:
12691801
89.

Acute disseminated encephalomyelitis after bee sting.

Boz C, Velioglu S, Ozmenoglu M.

Neurol Sci. 2003 Feb;23(6):313-5.

PMID:
12624719
90.

Relationship between major depression and heart rate variability. Clinical consequences and implications for antidepressive treatment.

Agelink MW, Boz C, Ullrich H, Andrich J.

Psychiatry Res. 2002 Dec 15;113(1-2):139-49.

PMID:
12467953
91.

X-linked spinal and bulbar muscular atrophy without proximal atrophy.

Boz C, Sahin N, Kalay E, Velioglu S, Ozmenoglu M.

Clin Neurol Neurosurg. 2002 Dec;105(1):14-7.

PMID:
12445917
92.

Baclofen is effective in intractable hiccups induced by brainstem lesions.

Boz C, Velioglu S, Bulbul I, Ozmenoglu M.

Neurol Sci. 2001 Oct;22(5):409. No abstract available.

PMID:
11917982
93.

Evaluation of plasma endothelin-1 levels in patients with cerebral infarction.

Alioğlu Z, Orem A, Bülbül I, Boz C, Ozmenoğlu M, Vanizor B.

Angiology. 2002 Jan-Feb;53(1):77-82.

PMID:
11863313
94.

Status epilepticus after stroke.

Velioğlu SK, Ozmenoğlu M, Boz C, Alioğlu Z.

Stroke. 2001 May;32(5):1169-72.

PMID:
11340227
95.

Increased plasma endothelin-1 levels in patients with intracerebral hemorrhage.

Alioğlu Z, Bülbül I, Orem A, Ozmenoğlu M, Vanizor B, Boz C.

J Stroke Cerebrovasc Dis. 2000 Jul-Aug;9(4):176-80. doi: 10.1053/jscd.2000.7231.

PMID:
24192024

[/av_textblock]
[/av_four_fifth]

[av_one_fifth min_height=” vertical_alignment=” space=” custom_margin=” margin=’0px’ padding=’0px’ border=” border_color=” radius=’0px’ background_color=” src=” background_position=’top left’ background_repeat=’no-repeat’ animation=” mobile_breaking=” mobile_display=”]

[av_heading tag=’h5′ padding=’10’ heading=’Yayınları Oku’ color=” style=” custom_font=” size=” subheading_active=” subheading_size=’15’ custom_class=” admin_preview_bg=” av-desktop-hide=” av-medium-hide=” av-small-hide=” av-mini-hide=” av-medium-font-size-title=” av-small-font-size-title=” av-mini-font-size-title=” av-medium-font-size=” av-small-font-size=” av-mini-font-size=”][/av_heading]

[av_font_icon icon=’ue84e’ font=’entypo-fontello’ style=” caption=’Tüm Yayınlar’ link=’page,950′ linktarget=” size=’40px’ position=’center’ color=’#dddddd’ admin_preview_bg=”][/av_font_icon]

[/av_one_fifth]